Cutler Group’s Aratana Therapeutics, Inc. PETX Stock Holding History

Cutler Group’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-23,300	Closed	-$5K	–	7173
2017 Q2	$5K	Sell	23,300 -2,200	-9%	-$13.5K	﹤0.01%	4941
2017 Q1	$1K	Buy	+25,500	New	+$172K	﹤0.01%	6161
2016 Q4	–	Sell	-4,800	Closed	-$4K	–	7754
2016 Q3	$4K	Buy	4,800 +500	+12%	+$4.15K	﹤0.01%	5259
2016 Q2	$6K	Sell	4,300 -4,000	-48%	-$25.7K	﹤0.01%	4833
2016 Q1	$16K	Buy	+8,300	New	+$31.2K	﹤0.01%	3563

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cutler Group's PETX Position: Q3 2018 in Review

Cutler Group sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2018, closing a stake of 100 shares.

Cutler Group first reported a position in PETX in Q1 2016 and held it in 8 quarters. The position peaked at $17K in Q3 2016. 100 funds tracked by Wall St. Rank hold PETX as of Q3 2018.

Cutler Group reported no remaining Aratana Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Cutler Group sold 100 Aratana Therapeutics, Inc. shares in Q3 2018.
Cutler Group first reported a position in Aratana Therapeutics, Inc. in Q1 2016 and held it in 8 quarters.
Cutler Group's Aratana Therapeutics, Inc. position peaked at $17K in Q3 2016.
100 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2018.

Based on Cutler Group's 13F filing for Q3 2018, filed 7 Nov 2018.